BIM
VKTX icon

Bogle Investment Management’s Viking Therapeutics VKTX Stock Holding History

Bogle Investment Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-18,407
Closed -$80K – 353
2018
Q1 		$80K Buy
+18,407
New +$102K 0.01% 299

Other funds holding VKTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bogle Investment Management's VKTX Position: Q2 2018 in Review

Bogle Investment Management sold out of Viking Therapeutics (VKTX) in Q2 2018, closing a stake of 18,407 shares — an estimated $80K sold.

Bogle Investment Management first reported a position in VKTX in Q1 2018 and held it in 1 quarter. The position peaked at $80K in Q1 2018. 116 funds tracked by Wall St. Rank hold VKTX as of Q2 2018.

  • Bogle Investment Management reported no remaining Viking Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Bogle Investment Management sold 18,407 Viking Therapeutics shares in Q2 2018, an estimated $80K.
  • Bogle Investment Management first reported a position in Viking Therapeutics in Q1 2018 and held it in 1 quarter.
  • Bogle Investment Management's Viking Therapeutics position peaked at $80K in Q1 2018.
  • 116 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2018.

Based on Bogle Investment Management's 13F filing for Q2 2018, filed 13 Aug 2018.